Targeted β(-)-Particle Plus Conversion and Auger-Electron Therapy with (161)Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study

What Was Tested

The paper reports a study of Octreotide and Somatostatin, published as a randomized controlled trial.

Methods: In this randomized, crossover, prospective, single-center, open-label phase 0 study, 8 patients received 1 GBq of [161Tb]Tb-DOTA-LM3 and 1 GBq of [177Lu]Lu-DOTATOC, with a 4-wk interval between injections.

Who Took Part

According to the abstract, 8 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Octreotide study: the patients and staff both knew the treatment.

In the crossover set-up each of the patients took both Octreotide and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Octreotide, Neuroendocrine Tumors, Receptors, Somatostatin, Beta Particles, Electrons, Single Photon Emission Computed Tomography Computed Tomography and Pancreatic Neoplasms.

Author keywords: 161Tb, DOTA-LM3, DOTATOC, gastroenteropancreatic neuroendocrine tumors and peptide receptor radionuclide therapy.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Octreotide and Somatostatin in 8 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2026 (Journal of nuclear medicine : official publication, Society of Nuclear Medicine), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.